Gabriela Kramer-Marek: I have just presented the very first results of our recently initiated clinical study evaluating 89Zr-DFO-Atezolizumab in patients with newly diagnosed glioblastoma!

Gabriela Kramer-Marek: I have just presented the very first results of our recently initiated clinical study evaluating 89Zr-DFO-Atezolizumab in patients with newly diagnosed glioblastoma!

Gabriela Kramer-Marek: I have just presented the very first results of our recently initiated clinical study evaluating 89Zr-DFO-Atezolizumab in patients with newly diagnosed glioblastoma!

Gabriela Kramer-Marek: I have just presented the very first results of our recently initiated clinical study evaluating 89Zr-DFO-Atezolizumab in patients with newly diagnosed glioblastoma!

Gabriela Kramer-Marek: I have just presented the very first results of our recently initiated clinical study evaluating 89Zr-DFO-Atezolizumab in patients with newly diagnosed glioblastoma!

Gabriela Kramer-Marek: I have just presented the very first results of our recently initiated clinical study evaluating 89Zr-DFO-Atezolizumab in patients with newly diagnosed glioblastoma!

Gabriela Kramer-Marek: I have just presented the very first results of our recently initiated clinical study evaluating 89Zr-DFO-Atezolizumab in patients with newly diagnosed glioblastoma!

Gabriela Kramer-Marek: I have just presented the very first results of our recently initiated clinical study evaluating 89Zr-DFO-Atezolizumab in patients with newly diagnosed glioblastoma!

Gabriela Kramer-Marek